Alivus Life Sciences Management Guidance Tracker
12 forward-looking guidance items tracked across 3 quarters.
Revenue
Management reaffirmed guidance of high single-digit revenue growth for FY26, driven by stronger H2 performance from non-GPL business, GPL recovery, and CDMO ramp-up.
Q3 FY26Revenue growth: high single-digit for FY26TrackedManagement expects high single-digit revenue growth for FY26, driven by non-GPL segment and CDMO ramp-up.
Margins
Management expects to sustain EBITDA margins around 30% despite absence of PLI benefits, supported by new launches and operational efficiency.
Q3 FY26EBITDA margin guidance raised to 30-32%ActiveEBITDA margin expected to be in 30-32% range going forward, up from earlier guidance of 28-30%.
Q4 FY26EBITDA margin guidance of 30-32% for FY27TrackedManagement expects to sustain EBITDA margins in the range of 30-32% for FY27, despite geopolitical headwinds.
Capex
Management guided for capex of approximately ₹250 crore in H2 FY26, with total FY26 capex expected to be lower than the board-approved ₹600 crore.
Q3 FY26Capex guidance reduced to ₹450 crore for FY26TrackedCapex for FY26 now guided at ₹450 crore, down from ₹600 crore, with ₹150 crore deferred to FY27.
Q4 FY26Capex of ~540 crore in FY27 funded internallyTrackedPlanned capex of about 540 crore for FY27, including carryover commitments and fresh investments, fully funded through internal accruals.
Growth
Management expects a meaningful turnaround in CDMO performance in H2, driven by new project additions and ramp-up of existing projects.
Q3 FY26CDMO: 1-2 new projects expected by Q1 FY27ActiveManagement expects to conclude 1-2 new CDMO projects by Q1 FY27, with early quantities already supplied.
Q4 FY26Two new CDMO deals expected in early H2 FY27TrackedManagement expects to close two new CDMO deals in the early second half of FY27, continuing momentum.